AC Immune SA (NASDAQ:ACIU) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 600,600 shares, a growth of 24.4% from the June 30th total of 482,900 shares. Approximately 1.9% of the company’s shares are short sold. Based on an average trading volume of 112,300 shares, the days-to-cover ratio is presently 5.3 days.
Shares of AC Immune stock opened at $5.41 on Thursday. AC Immune has a 1 year low of $3.25 and a 1 year high of $12.50. The stock has a 50-day simple moving average of $5.48. The company has a market capitalization of $368.89 million, a P/E ratio of -6.60 and a beta of 0.02. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.01.
AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Wednesday, May 15th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.36). The business had revenue of $75.28 million during the quarter, compared to the consensus estimate of $106.81 million. AC Immune had a return on equity of 12.17% and a net margin of 29.66%. On average, equities research analysts expect that AC Immune will post 0.17 EPS for the current fiscal year.
ACIU has been the subject of several recent analyst reports. ValuEngine upgraded AC Immune from a “sell” rating to a “hold” rating in a report on Wednesday, June 12th. HC Wainwright set a $8.00 price target on AC Immune and gave the stock a “buy” rating in a report on Friday, July 12th. Finally, BidaskClub upgraded AC Immune from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $11.94.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Story: Producer Price Index (PPI)
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.